Overview

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Status:
Not yet recruiting
Trial end date:
2027-03-15
Target enrollment:
Participant gender:
Summary
Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals